620633-04-7

Basic information

• Product Name: Oxazole, 4-(4-fluorophenyl)- (9CI)
• Synonyms: Oxazole, 4-(4-fluorophenyl)- (9CI);4-(4-fluorophenyl)oxazole
• CAS NO: 620633-04-7
• Molecular Formula: C₉H₆FNO
• Molecular Weight: 163.1484432
• Product Categories: HALIDE
• Mol File: 620633-04-7.mol

Chemical Properties

• Appearance: /
• Storage Temp.: 2-8°C
• CAS DataBase Reference: Oxazole, 4-(4-fluorophenyl)- (9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: Oxazole, 4-(4-fluorophenyl)- (9CI)(620633-04-7)
• EPA Substance Registry System: Oxazole, 4-(4-fluorophenyl)- (9CI)(620633-04-7)

Safety Data

• Hazardous Substances Data: 620633-04-7(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
Oxazole, 4-(4-fluorophenyl)(9CI) is used as a key intermediate in the synthesis of various pharmaceutical compounds for its potential biological activities. The 4-(4-fluorophenyl) substitution on the oxazole ring may enhance the compound's pharmacological properties, such as improving binding affinity to target proteins or modulating specific biological pathways.
Used in Medicinal Chemistry Research:
In the field of medicinal chemistry, Oxazole, 4-(4-fluorophenyl)(9CI) serves as a valuable research tool for the development of novel therapeutic agents. Its unique structure allows for the exploration of new chemical space and the design of innovative drug candidates with improved potency, selectivity, and pharmacokinetic properties.
Used in Chemical Synthesis Processes:
Oxazole, 4-(4-fluorophenyl)(9CI) is employed as a versatile building block in various chemical synthesis processes. Its reactivity and functional group compatibility make it suitable for the preparation of a wide range of organic compounds, including agrochemicals, dyes, and other specialty chemicals.
Used in Materials Science:
Oxazole, 4-(4-fluorophenyl)(9CI) may also find applications in materials science, where its unique structural features and potential interactions with other molecules could be harnessed to develop new materials with specific properties, such as improved stability, conductivity, or responsiveness to external stimuli.

Upstream product

• 64-18-6 formic acid 
• 16712-16-6 ammonium formate 
• 403-29-2 2-bromo-4'-fluoroacetophenone 

Downstream Products

• 883528-25-4 2-(4-fluorophenyl)isonicotinic acid 
• 620971-39-3 1-(6-{4-[4-(4-Fluoro-phenyl)-oxazol-2-yl]-phenoxy}-pyridin-3-yl)-pyrrolidine-2,2-dicarboxylic acid diethyl ester 
• 1552273-95-6 1-cyclopentyl-4-(4-fluorophenyl)-1H-imidazole 

Relevant articles and documents

SUBSTITUENT-INCLUDING UREA COMPOUND

An object of the present invention is to provide a compound that has a specific chemical structure having an activation effect on SIRT6 and is useful as an active component for preventing and treating inflammatory diseases. The present invention relates to a compound represented by Formula (1) or a pharmaceutically acceptable salt thereof. (Each symbol in Formula (1) has the same definition as that described in the specification.)

Discovering novel chemical inhibitors of human cyclophilin A: Virtual screening, synthesis, and bioassay

Cyclophilin A (CypA) is a member of cyclophilins, a family of the highly homologous peptidyl prolyl cis-trans isomerases (PPIases), which can bind to cyclosporin A (CsA). CypA plays critical roles in various biological processes, including protein folding, assembly, transportation, regulation of neuron growth, and HIV replication. The discovery of CypA inhibitor is now of a great special interest in the treatment of immunological disorders. In this study, a series of novel small molecular CypA inhibitors have been discovered by using structure-based virtual screening in conjunction with chemical synthesis and bioassay. The SPECS_1 database containing 85,000 small molecular compounds was searched by virtual screening against the crystal structure of human CypA. After SPR-based binding affinity assay, 15 compounds were found to show binding affinities to CypA at submicro-molar or micro-molar level (compounds 1-15). Seven compounds were selected as the starting point for the further structure modification in considering binding activity, synthesis difficulty, and structure similarity. We thus synthesized 40 new small molecular compounds (1-6, 15, 16a-q, 17a-d, and 18a-l), and four of which (compounds 16b, 16h, 16k, and 18g) showed high CypA PPIase inhibition activities with IC50s of 2.5-6.2 μM. Pharmacological assay indicated that these four compounds demonstrated somewhat inhibition activities against the proliferation of spleen cells.

Triaryl-oxy-aryl-spiro-pyrimidine-2,4,6-trione metalloproteinase inhibitors

The present invention relates to triaryl-oxy-aryl-spiro-pyrimidine-2,4,6-trione metalloproteinase inhibitors of the formula 1wherein said ring X is a 5-7 membered heterocyclic ring, and wherein A, Y, B, G, and W are as defined in the specification; and t